Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons’ Referrals

Adjuvant Chemotherapy in Resected Lung Cancer: Two-Year Experience in a University Hospital

(2016) Nicole Bouchard et al.   Canadian Respiratory Journal

Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives

(2014) Zhong Yuan et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

(2013) A. Schneeweiss et al.   ANNALS OF ONCOLOGY

How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study

(2012) Robin Urquhart et al.   Implementation Science

Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer

(2012) Tatiana M. Prowell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adherence to Clinical Practice Guidelines for Adjuvant Chemotherapy for Colorectal Cancer in a Canadian Province: A Population-Based Analysis

(2012) Daniel Rayson et al.   Journal of Oncology Practice

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

(2010) Luca Gianni et al.   LANCET

Valuing citizen and patient preferences in health: recent developments in three types of best–worst scaling

(2010) Terry N Flynn   Expert Review of Pharmacoeconomics & Outcomes Research